

Date: 17/01/2020

FREEDOM OF INFORMATION REQUEST - Ref: FOI/015129 – Biologics and Biosimilar prescribing in Rheumatology

Drug Name	No. of patients treated 2019
• Abatacept [Orencia]	85
• Adalimumab [Amgevita]	2
• Adalimumab [Hulio]	0
• Adalimumab [Humira]	369
• Adalimumab [Hyrimoz]	233
• Adalimumab [Imraldi]	0
• Apremilast [Otezla]	0
• Baricitinib [Olumiant]	42
• Brodalumab [Kyntheum]	0
• Certolizumab [Cimzia]	47
• Dimethyl fumarate [Skilarence]	3
• Etanercept [Benepali]	403
• Etanercept [Enbrel]	68
• Etanercept [Erelzi]	0
• Golimumab [Simponi]	71
• Guselkumab [Tremfya]	6
• Infliximab [Flixabi]	0
• Infliximab [Inflectra]	0
• Infliximab [Remicade]	4
• Infliximab [Remsima]	146
• Ixekizumab [Taltz]	9
• Risankizumab [Skyrizi]	0
• Rituximab [MabThera]	60
• Rituximab [Rixathon]	0
• Rituximab [Truxima]	155
• Sarilumab [Kevzara]	0
• Secukinumab [Cosentyx]	259
• Tildrakizumab [Ilumetri]	0
• Tocilizumab [Ro Actemra]	123
• Tofacitinib [Xeljanz]	13
• Upadacitinib [Rinvoq]	0
• Ustekinumab [Stelara]	134